Annual Test + MetaVasc Capsules for $55/month! (one-time fee $199)
Heart health, fatty liver, metabolic health, diabetes, insulin resistance, inflammation, longevity

Live Better, Longer (and lighter).


Get advanced CardioMetaboliQ testing, lose more weight,
and get FREE annual retests! *


Subjects lost 60-90% more weight and 7X the liver fat compared to 400 cal/day reduction alone.(1) * Free annual re-tests with Clinical Healthy Weight Package, save $345 in the first year!

The CardioMetaboliQ + MetaVasc Solution

The CardioMetaboliQ + MetaVasc Solution.

Standard blood labs are missing a lot. CardioMetaboliQ™️ tests residual heart risk, fatty liver index, early metabolic dysfunction, and more.

Liver Fat - Inflammation - Cholesterol - Body Weight - Blood Sugar - Insulin Sensitivity - Visceral Fat - Oxidative Stress - Residual Heart Disease Risk - Metabolic Risk

The CardioMetaboliQ + MetaVasc Solution

Clinical Healthy Weight Package: $199 + $55/mo billed quarterly

Includes $345 Savings over first year:

-CardioMetaboliQ™️ Blood Test (home blood spot or LabCorp)

-Lowest Price Monthly MetaVasc®️Capsules*

-Free Bottle of MetaVasc®️Capsules

-Free Annual Retest**

* MetaVasc is a proprietary formula with BergacynFF®️(Citrus Bergamot, Cynara artichoke), Curcugen®️ Ultra Curcumin, Berberine, PQQ and Chromium Picolinate.
** After 12 months of continual MetaVasc purchase.

The CardioMetaboliQ + MetaVasc Solution

No doctor’s office or lab visit required. Just the best of science and nature together, period.

No doctor’s office or lab visit required. Just the best of science and nature together, period.


Optimize your heart and liver health together, and lose 60-90% more weight(1) with CardioMetaboliQ and MetaVasc together!


The CardioMetaboliQ + MetaVasc Solution

Pricing for Tests Purchased Separately

The CardioMetaboliQ™️ Test is available in 3 versions:

-At-Home blood spot test: $199

-LabCorp blood draw: $199

-Provide your own lab data: $139

Shop Tests

Up to 75% of heart attacks occur in “healthy” or statin “managed” people.

Up to 75% of heart attacks occur in “healthy” or statin “managed” people.

Standard testing misses residual heart risk. You can choose smarter CardioMetaboliQ testing that better evaluates residual risk, and provides a 12-page in-depth report, empowering you to make effective changes for greater healthspan.

It’s your choice.

Shop Now

Save Money with a Subscription!

Annual, monthly or all-inclusive!

-Healthy Weight Package: $199 + $55/mo

-Annual subscription: $129

-Monthly subscription: $69 + $12.99/mo

Explore Subscriptions

Did you know your risk for heart attack is affected by your liver?

Did you know your risk for heart attack is affected by your liver?

We now know how to evaluate heart risk, liver health and diabetes risk more accurately than ever before.

And we know how to greatly improve liver fat levels and function with MetaVasc Capsules.

But you won’t get these tests or this proprietary nutraceutical anywhere else!


CardioMetaboliQ FAQ’s

What is Residual Heart Disease Risk?

▪️Each year, roughly 600,000 US adults have “healthy heart attacks” with “normal” blood test results. That’s >1 every minute.(2)

▪️And almost 75% of the people who have heart attacks do not have dangerous levels of LDL cholesterol.(2)

▪️Unfortunately, large studies now confirm that statin medications only reduce heart attack risk by 17% and cardiovascular death by only 6% vs placebo.(13)

-So, CardioMetaboliQ tests the markers that show “residual risk”, which is responsible for heart attacks and strokes in statin “controlled” patients with “normal” blood tests.

Residual risk markers include Remnant Cholesterol, CRP, AIP, FLI and TyG; these are advanced cardiovascular risk
indicators which reveal residual heart disease risk more accurately than LDL cholesterol alone.(3,4,5)

Only 6.3% of US Adults are currently in “optimal cardiometabolic health”(17)

-A large analysis in 2018, by O’Hearn et al, found 93% of US adults were in “less than optimal cardiometabolic health”.

-The yearly US cost of cardiometabolic disease is currently about $500 billion, and rising. Effectively testing cardiovascular, liver and metabolic systems together can provide timely awareness to reduce risk of disease progression.

-Cardiometabolic health is assessed based on liver, cardiovascular and metabolic health. Metabolic health refers primarily to blood sugar and lipid metabolism and, when dysfunctional, leads to prediabetes, diabetes, insulin resistance and metabolic syndrome. Neurological conditions such as Alzheimer’s Disease and neurocognitive decline and dementia are also closely related to metabolic disease.

-Liver diseases such as Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Hepatic Steatosis, cirrhosis and liver cancer are intimately associated with cardiometabolic physiology and disease.

-Cardiovascular diseases including coronary artery disease, atherosclerosis are a part of cardiometabolic disease. These conditions can be worsened by metabolic and liver dysfunction.

What is Insulin Resistance and why is it important?

-Insulin Resistance refers to the reduced capacity for the body to respond to insulin signaling and thereby maintain appropriate blood sugar regulation and metabolic homeostasis.

-Insulin Resistance is critically important because it often begins many years in advance of other metabolic conditions such as prediabetes, metabolic syndrome and diabetes.

What is Fatty Liver Disease and why is it important?

Fatty Liver Disease refers to an increase in the concentration of fat deposits in the liver, generally brought about by excess caloric intake and insufficient exercise. Many people with this condition are unaware that they have it.

More than 80 million Americans have Non Alcoholic Fatty Liver Disease (NAFLD), a condition which can worsen diabetes and heart disease, and increases risk of liver and other cancers.(6)

-So we provide the Fatty Liver Index to check liver fat content and assess whether NAFLD may be an concern.(16,18)

-MetaVasc®️Capsules contain a branded patented ingredient called BergacynFF, which has been clinically shown in human studies to reduce liver fat levels and improve several cardiometabolic parameters including inflammation, cholesterol, blood sugar, body weight, BMI, oxidative stress and vascular endothelial function.

Is Alzheimer’s Disease affected by cardiometabolic health?

-Alzheimer’s Disease is sometimes referred to as Type 3 Diabetes, because the effects of glycemic dysregulation (blood sugar mismanagement) are strongly seen as contributing to Alzheimer’s Disease progression and the risk and development of other neurocognitive conditions.

More than 6 million US adults have Alzheimer’s Disease.(8)

-Studies indicate that Alzheimer’s risk can be as much as 69% higher with elevated Insulin Resistance (TyG), even with blood lab results considered to be within standard or “normal” range.(9)

Click to see references for statements above.
(1) Ferro, Yvelise et al. “Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-diabetic Individuals Aged Over 50 Years.”Frontiers in endocrinologyvol. 11 494. 11 Aug. 2020, doi:10.3389/fendo.2020.00494

(2)https://www.health.harvard.edu/heart-health/subclass-of-ldl-cholesterol-may-predict-heart-disease#:~:text=High%20levels%20of%20low%2Ddensity,have%20dangerously%20high%20LDL%20levels.

(3) Quispe, Renato et al. “Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.”European heart journal, vol. 42,42 (2021): 4324-4332. doi:10.1093/eurheartj/ehab432
(4) Castañer O, Pintó X, Subirana I, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease.J Am Coll Cardiol. 2020;76(23):2712-2724. doi:10.1016/j.jacc.2020.10.008
(5) Mangalesh S, Yadav P, Dudani S, Mahesh NK. Atherogenic index of plasma predicts coronary artery disease severity and major adverse cardiac events in absence of conventional risk factors.Coron Artery Dis. 2022;33(7):523-530. doi:10.1097/MCA.0000000000001166
(6)https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease
(7) Musolino, Vincenzo et al. “The synergistic effect ofCitrus bergamiaandCynara cardunculusextracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease.”Journal of traditional and complementary medicinevol. 10,3 268-274. 8 Feb. 2020, doi:10.1016/j.jtcme.2020.02.004
(8)https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
(9) Sun J, Xie Z, Wu Y, et al. Association of the Triglyceride-Glucose Index With Risk of Alzheimer's Disease: A Prospective Cohort Study [published online ahead of print, 2023 Jul 26].Am J Prev Med. 2023;S0749-3797(23)00312-4. doi:10.1016/j.amepre.2023.07.011
(10)https://www.cdc.gov/heartdisease/facts.htm#:~:text=Every%20year%2C%20about%20805%2C000%20people,States%20have%20a%20heart%20attack.&text=Of%20these%2C,are%20a%20first%20heart%20attack.
(11) Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023 Oct 16;10:1264319. doi: 10.3389/fcvm.2023.1264319. PMID: 37908502; PMCID: PMC10613690.
(12) Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK507839/
(13) Cordero, Alberto et al. “The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.”Journal of clinical lipidology, S1933-2874(23)00252-0. 22 Aug. 2023, doi:10.1016/j.jacl.2023.08.006
(14) Moon, Joon Ho et al. “Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study.”Endocrinology and metabolism (Seoul, Korea)vol. 38,4 (2023): 406-417. doi:10.3803/EnM.2023.1703
(15) Xuan, Wenting et al. “Impacts of Triglyceride Glucose-Waist to Height Ratio on Diabetes Incidence: A Secondary Analysis of A Population-Based Longitudinal Data.”Frontiers in endocrinologyvol. 13 949831. 22 Jul. 2022, doi:10.3389/fendo.2022.949831
(16) Basheer, Maamoun et al. “Liver Fat Storage Is a Better Predictor of Coronary Artery Disease than Visceral Fat.”Metabolitesvol. 13,8 896. 28 Jul. 2023, doi:10.3390/metabo13080896
(17) O'Hearn, Meghan et al. “Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018.”Journal of the American College of Cardiology, vol. 80,2 (2022): 138-151. doi:10.1016/j.jacc.2022.04.046
(18) Li C, Guo P, Zhang R, et al. Both WHR and FLI as Better Algorithms for Both Lean and Overweight/Obese NAFLD in a Chinese Population.J Clin Gastroenterol. 2019;53(6):e253-e260. doi:10.1097/MCG.0000000000001089
Click to see BioCalculators and Related Research


The calculators below can be a great way to see how your health risks can be improved by changes to personal health characteristics.

By using the results from your CardioMetaboliQ™️ blood test, you can calculate various health risk profiles for yourself, like atherosclerosis, diabetes and fatty liver.

Then, by projecting improvements in areas like waist size, cholesterol and triglyceride levels, blood sugar, and blood pressure, you can target reductions in your health risks.


CardioPredict™️ BioCalculators

1) Atherosclerosis (ASCVD) Risk Assessment Calculator

https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/advice/riskgraph/

2) Fatty Liver Index (FLI) Calculator

https://www.mdapp.co/fatty-liver-index-fli-calculator-356/

3) Triglyceride-Glucose Index (TyG) Calculator

https://dremilyfranklin.com/triglyceride-glucose-index/

4) Atherogenic Index of Plasma (AIP) Calculator

https://www.evidencio.com/models/show/1141

5) Findrisc Diabetes Risk Calculator

https://reference.medscape.com/calculator/236/findrisc-diabetes-risk-calculator

6) Carbohydrate Intake for Weight Management Calculator

https://www.mdapp.co/carbs-calculator-daily-carbohydrate-intake-220/

7) Body Mass Index (BMI) Calculator

https://www.mdapp.co/bmi-calculator-64/

Related Research Studies

The studies listed below apply the markers found in the CardioMetaboliQ™️ test to different health conditions.

(to open studies, copy & paste the bold “doi” link into PubMed search bar)

1) Zhou, Jing et al. “Fatty Liver Index and Its Association with 10-Year Atherosclerotic Cardiovascular Disease Risk: Insights from a Population-Based Cross-Sectional Study in China.” Metabolitesvol. 13,7 850. 14 Jul. 2023, doi:10.3390/metabo13070850

2) Weaver, Olivia R et al. “Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.”CMAJ openvol. 11,4 E645-E653. 25 Jul. 2023, doi:10.9778/cmajo.20210318

3) Sun, Junyi et al. “Association of the Triglyceride-Glucose Index With Risk of Alzheimer's Disease: A Prospective Cohort Study.”American journal of preventive medicine, S0749-3797(23)00312-4. 26 Jul. 2023, doi:10.1016/j.amepre.2023.07.011

4) Tarantino, Giovanni et al. “Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study.”Journal of clinical medicinevol. 10,2 346. 18 Jan. 2021, doi:10.3390/jcm10020346

5) Ding, Xiaobo et al. “Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies.”Cardiovascular diabetologyvol. 20,1 76. 3 Apr. 2021, doi:10.1186/s12933-021-01268-9

6) Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023 Oct 16;10:1264319. doi: 10.3389/fcvm.2023.1264319. PMID: 37908502; PMCID: PMC10613690.

7) Huang, Qin et al. “Association of novel lipid indicators with the risk of stroke among participants in Central China: a population-based prospective study.”Frontiers in endocrinologyvol. 14 1266552. 2 Oct. 2023, Huang, Qin et doi:10.3389/fendo.2023.1266552

8) Zhang, Peng et al. “The Role of Remnant Cholesterol Beyond Low-Density Lipoprotein Cholesterol in Arterial Stiffness: A Cross-Sectional Study.”Metabolic syndrome and related disorders, 10.1089/met.2023.0101. 30 Oct. 2023, doi:10.1089/met.2023.0101

Advanced Science meets the Power of Nature

Advanced Science meets the Power of Nature



Get leading-edge lab testing and validated natural therapeutics.

CardioMetaboliQ + MetaVasc

A lab report made for you, the patient.

How many of us have had labs run only to get no feedback at all from our doctor?

Not here. We draw on over 15 years of clinical functional medicine experience to create a 12-page personalized report that’s built for the patient.

Your healthcare provider will appreciate the detailed information, but the report is designed for you to understand your results and the best action steps to maximize your health and wellness!

Some things just go together.

Some things just go together.

Move beyond standard testing and see the whole picture with CardioMetaboliQ.

Then use MetaVasc Capsules for clinically proven results.

Explore the CardioMetaboliQ+MetaVasc Solution!